Profile data is unavailable for this security.
About the company
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
- Revenue in USD (TTM)145.67m
- Net income in USD-89.91m
- Incorporated2008
- Employees325.00
- LocationKaryopharm Therapeutics Inc85 Wells Avenue, Second FloorNEWTON 02459United StatesUSA
- Phone+1 (617) 658-0600
- Fax+1 (302) 655-5049
- Websitehttps://karyopharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Armata Pharmaceuticals Inc | 3.72m | -67.04m | 86.84m | 66.00 | -- | -- | -- | 23.35 | -1.95 | -1.95 | 0.0893 | -1.28 | 0.0355 | -- | 0.7532 | 56,348.48 | -64.00 | -59.78 | -385.50 | -72.70 | -- | -- | -1,802.72 | -1,113.72 | -- | -1.99 | 1.71 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Allovir Inc | 0.00 | -140.34m | 88.31m | 112.00 | -- | 0.7338 | -- | -- | -1.23 | -1.23 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -67.85 | -52.85 | -73.72 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| Hillevax Inc | 0.00 | -156.27m | 89.61m | 90.00 | -- | 0.4329 | -- | -- | -3.38 | -3.38 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -55.47 | -- | -63.02 | -- | -- | -- | -- | -- | -- | -- | 0.1113 | -- | -- | -- | 22.68 | -- | -- | -- |
| bluebird bio Inc | 45.69m | -302.96m | 91.18m | 375.00 | -- | 0.6946 | -- | 2.00 | -2.44 | -2.44 | 0.3452 | 0.677 | 0.069 | 3.28 | -- | 121,837.30 | -45.76 | -34.75 | -66.24 | -40.84 | -22.60 | -124.35 | -663.09 | -5,770.41 | 0.8219 | -28.60 | 0.615 | -- | 720.04 | -11.58 | 8.00 | -- | -30.47 | -- |
| Metagenomi Inc | 55.93m | -75.00m | 91.79m | 228.00 | -- | 0.3407 | -- | 1.64 | -2.53 | -2.53 | 1.68 | 7.19 | 0.1408 | -- | 28.13 | 236,987.30 | -18.88 | -- | -22.14 | -- | -- | -- | -134.10 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Karyopharm Therapeutics Inc | 145.67m | -89.91m | 92.02m | 325.00 | -- | -- | -- | 0.6317 | -0.8356 | -0.8356 | 1.17 | -1.06 | 0.5692 | 1.62 | 4.15 | 448,209.20 | -35.14 | -53.02 | -45.50 | -65.85 | 96.04 | 97.18 | -61.72 | -125.15 | 3.56 | -7.37 | 2.00 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| CytomX Therapeutics Inc | 119.57m | 11.09m | 92.96m | 120.00 | 8.68 | -- | 7.16 | 0.7775 | 0.1371 | 0.1371 | 1.45 | -0.3997 | 0.6491 | -- | 51.12 | 996,408.30 | 6.02 | -21.53 | 26.34 | -32.32 | -- | -- | 9.27 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Coya Therapeutics Inc | 9.55m | -10.10m | 93.00m | 8.00 | -- | 2.64 | -- | 9.73 | -0.7726 | -0.7726 | 0.7589 | 2.32 | 0.3512 | -- | -- | 1,194,290.00 | -37.13 | -- | -40.92 | -- | -- | -- | -105.71 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Medicinova Inc | 1.00m | -8.16m | 93.19m | 13.00 | -- | 1.62 | -- | 93.19 | -0.1665 | -0.1665 | 0.0204 | 1.17 | 0.0155 | -- | -- | 76,923.08 | -12.65 | -15.36 | -13.19 | -15.90 | -- | -- | -816.49 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Ikena Oncology Inc | 1.84m | -66.71m | 93.41m | 18.00 | -- | 0.5776 | -- | 50.66 | -1.43 | -1.43 | 0.0393 | 2.96 | 0.0112 | -- | -- | 42,883.72 | -40.52 | -29.72 | -43.17 | -34.62 | -- | -- | -3,617.57 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Benitec Biopharma Inc | 7.00k | -21.69m | 93.80m | 18.00 | -- | 2.20 | -- | 13,400.13 | -9.87 | -9.87 | 0.0031 | 4.22 | 0.0006 | -- | 0.1284 | 388.89 | -186.85 | -83.43 | -260.89 | -98.77 | 1,542.86 | 96.86 | -309,885.70 | -468.04 | -- | -307.03 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
| Oramed Pharmaceuticals, Inc. | 0.00 | 20.86m | 94.18m | 15.00 | 4.62 | 0.530 | 4.49 | -- | 0.4999 | 0.4999 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | 12.19 | -- | 12.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Immuneering Corp | 0.00 | -56.07m | 95.19m | 66.00 | -- | 1.44 | -- | -- | -1.91 | -1.91 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -55.52 | -- | -59.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -42.29m | 95.26m | 11.00 | -- | 1.21 | -- | -- | -3.91 | -3.91 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -94.50 | -232.67 | -129.40 | -- | -- | -- | -- | -- | -- | -323.10 | 0.0626 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Werewolf Therapeutics Inc | 9.28m | -53.73m | 95.71m | 45.00 | -- | 0.9201 | -- | 10.31 | -1.35 | -1.35 | 0.236 | 2.38 | 0.0548 | -- | 2.48 | 197,510.60 | -31.70 | -- | -34.39 | -- | -- | -- | -578.80 | -- | -- | -- | 0.1948 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Karyopharm Therapeutics Inc's reporting currency: US Dollar USD
38.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Avidity Partners Management LPas of 31 Mar 2024 | 8.30m | 6.66% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 8.11m | 6.51% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 7.84m | 6.30% |
| Palo Alto Investors LPas of 31 Mar 2024 | 5.10m | 4.09% |
| Eversept Partners LPas of 31 Mar 2024 | 5.02m | 4.03% |
| Adage Capital Management LPas of 31 Mar 2024 | 3.50m | 2.81% |
| Citadel Advisors LLCas of 31 Mar 2024 | 3.10m | 2.49% |
| Marshall Wace LLPas of 31 Mar 2024 | 2.60m | 2.08% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.29m | 1.83% |
| BNP Paribas Financial Marketsas of 31 Mar 2024 | 1.77m | 1.42% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
